Hepatic parenchymal vasoconstriction increases cytotoxic drug uptake into hepatic metastases by increasing the tumour to liver blood flow ratio. Prolonged infusion of the vasoconstrictor vasopressin does not result in sustained vasoconstriction, and this may limit the benefit of vasopressin in infusional chemotherapy. We have assessed whether loss of vasopressin-induced vasoconstriction is mediated by nitric oxide. Hepatic and tumour blood flow were continuously monitored, in an animal hepatic tumour model, by laser Doppler flowmetry. The response to regionally infused vasopressin and the nitric oxide inhibitor N-nitro-L-arginine methyl ester (L-NAME) were assessed over a 30 min infusion period. The vasopressin-induced vasoconstrictor effect diminished after 15min despite continued infusion. Vasoconstriction was significantly prolonged when L-NAME was infused in addition to vasopressin. The increase in tumour to normal blood flow ratio was greater over the infusion period when L-NAME was co-administered with vasopressin. Our results suggest that the loss of vasopressin-induced vasoconstriction seen in liver parenchyma after regional infusion is prevented by the nitric oxide synthase inhibitor L-name and may be mediated by nitric oxide. al., 1993). We have tested the hypothesis that the loss of vasoconstrictor effect seen in response to prolonged vasopressin infusion is due to local NO release. In order to do this, we have measured hepatic and tumour blood flow changes in response to regional vasopressin infusion with and without the addition of the specific nitric oxide inhibitor N-nitro-L-arginine methyl ester (L-NAME). Perfusion measurements Perfusion measurements were carried out using laser Doppler flowmetry (MBF3D; Moor Instruments), in which incident laser light (wavelength 780-820 nm) is scattered in the tissue and undergoes a frequency shift in proportion to red cell speed and concentration, and which has an estimated measuring depth of 1-2 mm. Laser Doppler output is recorded on an arbitrary scale in flux units which are proportional to tissue perfusion. A 30 x 1 mm surface probe was carefully applied to the surface of the liver using a probe holder to minimise movement between the probe tip and the liver surface. A second probe was similarly placed in contact with the tumour surface such that the measurements were from tumour tissue and not influenced by adjacent liver. Movement artefact was minimised by careful positioning of the probes using the lowest display time constant and a recording rate of 20 Hz. Subsequent readings were performed with a time constant of 3.0 s at 0.25 Hz and were measured for 10 min before and for 30 min during the infusion period. 
Hepatic artenral fluorodeoxyuridine (FUDR) infusion has been shown to confer a survival benefit (Rougier et al., 1992; Allen-Mersh et al., 1994 ) and a higher partial response than with systemic chemotherapy (Dworkin and Allen-Mersh, 1991) in the treatment of colorectal liver metastases. As a result, more patients with colorectal liver metastases will be offered regional infusional treatment.
Regionally infused vasoactive agents aim to increase the proportion of hepatic arterial blood flow to tumour as compared with normal liver and may be of benefit in enhancing the efficacy of regional infusion chemotherapy. We have previously shown a relationship between tumour blood flow and uptake of 5-fluorouracil (5-FU) (Dworkin et al., 1993) . Previous radiological studies using the parenchymal vasoconstrictor vasopressin to enhance tumour blush during angiography have suggested that the duration of effect of regional vasopressin on the hepatic arterial circulation is short (Conn et al., 1973) . Using regional angiotensin II, Sasaki et al. (1985) demonstrated a 3-fold increase in tumour blood flow, which was maximal within 1-2 min and decreased rapidly thereafter. We have shown (Dworkin et al., 1992 ) that after initial vasopressin-induced vasoconstriction there is a loss of effect despite continued infusion of the vasoactive agent. Following the identification of nitric oxide (NO) as an important vasodilator substance produced by endothelial cells (Moncada et al., 1991) , it has been shown that NO is the mediator of ATP-induced vasodilation in the hepatic arterial bed (Mathie et al., 1991) and may be involved with endothelin I in the regulation of basal sinusoidal tone within the liver (Kawada et al., 1993) . We have tested the hypothesis that the loss of vasoconstrictor effect seen in response to prolonged vasopressin infusion is due to local NO release. In order to do this, we have measured hepatic and tumour blood flow changes in response to regional vasopressin infusion with and without the addition of the specific nitric oxide inhibitor N-nitro-L-arginine methyl ester (L-NAME). Perfusion measurements Perfusion measurements were carried out using laser Doppler flowmetry (MBF3D; Moor Instruments), in which incident laser light (wavelength 780-820 nm) is scattered in the tissue and undergoes a frequency shift in proportion to red cell speed and concentration, and which has an estimated measuring depth of 1-2 mm. Laser Doppler output is recorded on an arbitrary scale in flux units which are proportional to tissue perfusion. A 30 x 1 mm surface probe was carefully applied to the surface of the liver using a probe holder to minimise movement between the probe tip and the liver surface. A second probe was similarly placed in contact with the tumour surface such that the measurements were from tumour tissue and not influenced by adjacent liver. Movement artefact was minimised by careful positioning of the probes using the lowest display time constant and a recording rate of 20 Hz. Subsequent readings were performed with a time constant of 3.0 s at 0.25 Hz and were measured for 10 min before and for 30 min during the infusion period. 
Regional infusions
Vasopressin (Sigma) and L-NAME (Sigma) were prepared at the start of each experiment by dissolving in 0.9% sodium chloride. Infusions were carried out directly via the gastroduodenal artery into the hepatic arterial circulation using an infusion pump (Harvard) at a rate of 50 minm-1. (Figure 1) .
If an infusion of L-NAME was added at the time when vasopressin-induced vasoconstriction was diminishing and perfusion starting to return to baseline levels (n = 3 animals), then the full vasoconstrictor response to vasopressin was restored in all cases (Figure 3 ). L-NAME administered alone caused a small but significant (P<0.001) fall in perfusion (mean flux fall 9.0%, s.d. 5.6%) which was maintained over the infusion compared with the saline group (mean flux increase 4.6%, s.d. 5.7%).
Twnour perfusion There was a significant fall in tumour perfusion at 30 min which was significantly (P<0.05) greater for both vasopressin (mean 20.4%, s.d. 20.0%) and the combined vasopressin/ L-NAME group (mean 36.0%, s.d. 26.7%) compared with saline (mean flux increase 3.5%, s.d. 13.7%) at the end of the infusion period (Figure 1 ). There was no significant difference (P = 0.15) between the vasopressin group and the combined vasopressin/L-NAME group.
The vasopressin-induced tumour perfusion fall was significantly (P<0.005) greater during the first half of the infusion period ( There was a significant (P <0.05) flux fall over the infusion period in the L-NAME only group (mean 17.5, s.d. 20. 3) compared with the saline control group (mean rise 0.9%, s.d. 10.2%), but this was not significantly different by 30 min from the onset of L-NAME infusion (Figure 1 ).
Twnour to normalflux ratio (TNR)
The average tumour to normal flux ratios over the entire infusion period were not significantly (P = 0.2) changed for the vasopressin group (mean increase 10.5%, s.d. 34.7%) compared with saline (mean fall 1.7%, s.d. 12.4%). However, this masked a rise in TNR for the first half of the infusion (mean increase 30.0%, s.d. 37.0%) which was significantly (P<0.0002) greater than the second half in which the TNR fell (mean fall 11.4%, s.d. 27.3%).
Combined vasopressin/L-NAME did produce a significant rise (P<0.02) in the average TNR for the infusion period (mean 67.6%, s.d. 62.5%) compared with saline (mean fall 1.7%, s.d. 12.4%). There was no significant (P = 0.10) differ- 
DisoB
Pressor agents such as vasopressin, angiotensin and adrenaline increase the tumour to liver parenchymal flow ratios for the delivery of microspheres and other tracer isotopes administered directly into the hepatic artery (Burton et al., 1985; Ackermann et al., 1988; Goldberg et al., 1991; Hemmingway et al., 1991) . This may be due to differences in the smooth muscle content of the arteriolar vessels of normal liver and tumour, resulting in a selective arterial vasoconstriction (Krylova, 1969) . Previous studies of the effects of vasoactive agents have used a short infusion or bolus doses of vasoactive agent. While this may be of benefit in enhancing the delivery of bolus chemotherapy or labelled microspheres, it cannot be assumed that the effect is sustained during prolonged vasoactive infusion as would be required with infusional chemotherapy. Previous studies have suggested that the potential benefit of vasoactive manipulation may only last a few minutes (Sasaki et al., 1985) . This study confirms the limited duration of the maximal vasoconstrictor effect of continued regional vasopressin infusion into the hepatic arterial circulation. It also shows that the tachyphylaxis effect which is seen approximately 15 min after commencement of vasopresin infusion is not seen throughout the 30 min study period when L-NAME is co-adminiser with vasopressin. This vasopressin tachyphylaxis effect might therefore be due to nitric oxide release within liver parenchymal vessels. Further studies in a more suitable long-term model would be necessary to determine whether the effect is sustained over a period of hours or days.
Vasopressin also produced a vasoconstriction within the tumour circulation, suggesting that the view of the tumour circulation as being unresponsive to pressor agents may not be correct. This response may have been produced by parenchymal vessels supplying the tumour or by tumour vessels. Tachyphylaxis to this effect was not apparent as in the liver parenchyma and, consequently, while the addition of L-NAME prolonged the effect of the first half of the infusion, there was no sigificant difference at the end of the infusion compared with vasopressin alone. This suggests that this vasoconstrictor effect arose from tumour vessels in which the role of nitric oxide in the regulation of vessel tone may not be the same as in normal vessels.
Despite the reduction in tumour flow with vasopressin there was an increase in tumour to normal flow ratio, offering the potential for therapeutic advantage by increasing the dose of the cytotoxic drug delivered. This effect was sustained by prolonging the effect of vasopressin infusion using L-NAME. Studies assessing the extent of the effect of combined vasopressin and L-NAME on tumour cytotoxic drug uptake in liver metastases would be justified. 
